- Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysisKenji Shima
Department of Medicine, Kawashima Hospital, Tokushima, Japan
Nephrology (Carlton) 15:632-8. 2010..No suitable index or optimal target for diabetic control has been established for diabetic patients with end-stage renal disease (ESRD) undergoing haemodialysis. To address these issues, the single-centre observational study was conducted...
- Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysisKenji Shima
Department of Medicine, Kawashima Hospital, Tokushima 770 8540, Japan
Ann Clin Biochem 49:68-74. 2012..However, it is unknown as to whether this is also true for diabetic patients with end-stage renal disease but not on haemodialysis...
- Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA)Keiko Chujo
Kawashima Hospital, Tokushima
J Med Invest 53:223-8. 2006..HbAlc levels for diabetics with ESRD were lower than indicated by their blood glucose control. When assessing blood glucose control based solely on HbAlc, erroneous results may be obtained. In such cases, GA may be used instead of HbAlc...
- Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetesKenji Shima
Department of Diabetes and Medicine, Kawashima Hospital, Japan
Intern Med 53:829-35. 2014..The aim of this study was to compare the utility of hemoglobin A1c (HbA1c) and glycated albumin (GA) for evaluating the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, in patients with type 2 diabetes...